GS LHF 75 mg Pill - pink capsule/oblong
Generic Name: dabrafenib
Pill with imprint GS LHF 75 mg is Pink, Capsule/Oblong and has been identified as Tafinlar 75 mg. It is supplied by GlaxoSmithKline.
Tafinlar is used in the treatment of Melanoma, Metastatic; Thyroid Cancer; Non Small Cell Lung Cancer; Low-Grade Glioma; Solid Tumors and belongs to the drug class multikinase inhibitors. There is positive evidence of human fetal risk during pregnancy. Tafinlar 75 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for GS LHF 75 mg
Tafinlar
- Generic Name
- dabrafenib
- Imprint
- GS LHF 75 mg
- Strength
- 75 mg
- Color
- Pink
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- GlaxoSmithKline
- Inactive Ingredients
-
silicon dioxide,
magnesium stearate,
microcrystalline cellulose,
hypromelloses,
ferric oxide red,
titanium dioxide
Note: Inactive ingredients may vary.
Labelers / Repackagers
NDC Code | Labeler / Repackager |
---|---|
00173-0847 (Discontinued) | GlaxoSmithKline |
00078-0681 | Novartis Pharmaceuticals Corporation |
More about Tafinlar (dabrafenib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.